Perfusion in erythromelalgia. J Invest Dermatol 2002, 118:699?03.16. Orstavik K, Weidner C, Schmidt R, Schmelz M, Hilliges M, Jorum E, Handwerker H, Torebjork E: Pathological C-fibres in sufferers using a chronic painful condition. Brain 2003, 126:567?78. 17. Davis MD, Sandroni P, Rooke TW, Low PA: Erythromelalgia: vasculopathy, neuropathy or each? Arch Dermatol 2003, 139:1337?343. 18. Kim MK, Yuk JW, Kim HS, Park KJ, Kim DS: Autonomic dysfunction in SCN9A-associated major erythromelalgia. Clin Auton Res 2013, 23:105?07. 19. Cummins TR, Dib-Hajj SD, Waxman SG: Electrophysiological properties of mutant Nav1.7 sodium channels inside a painful inherited neuropathy. J Neurosci 2004, 24:8232?236. 20. Cheng X, Dib-Hajj SD, Tyrrell L, Te Morsche RH, Drenth JP, Waxman SG: Deletion mutation of sodium channel Na(V)1.7 in inherited erythromelalgia: enhanced slow inactivation modulates dorsal root ganglion neuron hyperexcitability. Brain 2011, 134:1972?986. 21. Dib-Hajj SD, Cummins TR, Black JA, Waxman SG: From genes to pain: Nav1.7 and human pain issues. Trends Neurosci 2007, 30:555?63. 22. Drenth JP, Waxman SG: Mutations in sodium channel gene SCN9A cause a spectrum of human genetic discomfort disorders. J Clin Invest 2007, 117:3603?609. 23. Dib-Hajj SD, Yang Y, Black JA, Waxman SG: The Nav1.7 sodium channel: from molecule to man. Nat Rev Neurosci 2012, 14:49?two. 24. Min-Tzu W, Po-Yuan H, Chen-Tung Y, Chih-Cheng C, Ming-Jen L: A novel SCN9A mutation responsible for primary erythromelalgia and is resistant for the therapy of sodium channel blockers. PLoS 1 2013, 8:e55212. 25. Skeik N, Rooke TW, Davis MD, Davis DM, Kalsi H, Kurth I, Richardson RC: Severe case and literature critique of principal erythromelalgia: novel SCN9A gene mutation. Vasc Med 2012, 17:44?9. 26. Bada JL: Treatment of erythromelalgia with propranolol [letter]. Lancet 1977, two:412. 27. Ozsoylu S, Caner H, G alp A: Prosperous treatment of erythromelalgia with sodium nitroprusside. J Pediatr 1979, 94:619?21. 28. Nathan A, Rose JB, Guite JW, Hehir D, Milovcich K: Main erythromelalgia inside a child responding to intravenous lidocaine and oral mexiletine therapy. Pediatrics 2005, 115:e504 507. 29. Cohen JS: High-dose oral magnesium treatment of chronic, intractable erythromelalgia. Ann Pharmacother 2002, 36:255?60. 30. Davis MD, Sandroni P: Lidocaine patch for discomfort of erythromelalgia: follow-up of 34 patients. Arch Dermatol 2005, 141:1320?321. 31. Iqbal J, Bhat MI, Charoo BA, Syed WA, Sheikh MA, Bhat IN: Expertise with oral mexiletine in principal erythromelalgia in youngsters.Buy7-Chloropyrido[3,4-b]pyrazine Ann Saudi Med 2009, 29:316?18.3-Bromo-5-methylpyrazin-2(1H)-one Chemscene 32.PMID:33557960 Legroux-Crespel E, Sassolas B, Guillet G: Remedy of familial erythermalgia with the association of lidocaine and mexiletine. Ann Dermatol Venereol 2003, 130:429?33. 33. Goldberg YP, Price tag N, Namdari R, Cohen CJ, Lamers MH, Winters C, Value J, Young CE, Verschoof H, Sherrington R, Pimstone SN, Hayden MR: Therapy of Nav1.7-mediated discomfort in inherited erythromelalgia utilizing a novel sodium channel blocker. Discomfort 2012, 153:80?five. 34. Davis MD, Rooke T: Erythromelalgia. Present Therapy Choices in Cardiovascular Medicine 2006, eight:153?65. 35. Fischer TZ, Gilmore ES, Estacion M, Eastman E, Taylor S, Melanson M, Dib-Hajj SD, Waxman SG: A novel Nav1.7 mutation making carbamazepine-responsive erythromelalgia. Ann Neurol 2009, 65:733?41. 36. Yang Y, Dib-Hajj SD, Zhang J, Zhang Y, Tyrrell L, Estacion M, Waxman SG: Structural modeling and mutant cycle evaluation predict pharmacoresponsiveness of a.